News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moomoo Market update
This document is a company profile and introduction for Tiziana Life Sciences. It likely provides an overview of the company's operations, mission, and perhaps its key products or research areas.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Tiziana Life Sciences has filed for Orphan Drug Designation with the FDA for its intranasal foralumab to treat Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disorder with no approved disease-modifying therapies. The company is currently evaluating foralumab in a Phase 2a โฆ
Tiziana Life Sciences (NASDAQ:TLSA) has applied for orphan drug designation from the FDA for its intranasal foralumab to treat multiple system atrophy (MSA). MSA is a rare, rapidly progressive neurodegenerative disease with no current disease-modifying therapies. If granted, the designation would provide significant benefits, โฆ
The article reports on a Form 4 filing for Tiziana Life Sciences Ltd, specifically for September 30. Form 4 filings are regulatory documents that disclose changes in ownership of company stock by insiders. The article indicates this filing is for the date mentioned.
Tiziana Life Sciences (TLSA) CEO Ivor Elrifi converted 1.05 million restricted stock units (RSUs) into common shares on August 15, 2026. Following this transaction, Elrifi now holds 5,843,684 common shares indirectly through a trust, in addition to 2,100,000 RSUs. The RSUs were granted on โฆ
Tiziana Life Sciences has dosed the first three patients in its Phase 2a Healey ALS MyMatch BANYAN clinical trial for intranasal foralumab, a potential treatment for amyotrophic lateral sclerosis (ALS). The trial, co-funded by the ALS Association, will assess the safety and tolerability of โฆ
This article provides a wrap-up of news from several small-cap companies. Key updates include Nvidia's additional $150 billion share repurchase authorization, NextSource Materials' US$30 million investment for a 15% stake in its battery anode facility, and Reconnaissance Energy Africa's discovery of thermogenic gas with โฆ
Tiziana Life Sciences has dosed the first three participants in its Phase 2a BANYAN clinical trial for intranasal foralumab, an anti-CD3 monoclonal antibody, aimed at treating early amyotrophic lateral sclerosis (ALS). The study, co-funded by the ALS Association, plans to enroll 44 individuals and โฆ
Tiziana Life Sciences has announced that the first three participants have been dosed in its Phase 2a Healey ALS MyMatch BANYAN clinical trial for intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The trial, co-funded by the ALS Association, evaluates foralumab in people with โฆ
Tiziana Life Sciences has dosed the first three participants in its Phase 2a Healey ALS MyMatch BANYAN trial for intranasal foralumab, a drug co-funded by the ALS Association. The trial aims to evaluate the drug's biological effect on the Treg pathway in ALS patients โฆ
Tiziana Life Sciences Ltd has begun dosing patients in its Phase 2a trial for intranasal foralumab in individuals with amyotrophic lateral sclerosis (ALS). The trial, co-funded by the ALS Association, will enroll 44 early ALS patients to evaluate the safety, tolerability, and biological effects โฆ
This article provides a 'small cap wrap' detailing recent news from several companies including Tiziana Life Sciences, First Phosphate, Ocean Power Technologies, and Midnight Sun Mining. Key updates include Tiziana Life Sciences completing a Phase 2a clinical trial, First Phosphate's deposit being confirmed as โฆ
BTIG has reiterated its Buy rating for Tiziana Life Sciences (TLSA.US) and maintained its price target of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Tiziana Life Sciences (TLSA) announced that the last patient has completed their visit in the Phase 2a INFORM-MS trial for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. The company expects to release topline data from the 12-week trial in October, following a database โฆ
Tiziana Life Sciences (TLSA) announced that the last patient has completed their final visit in the Phase 2a INFORM-MS clinical trial for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The company expects to lock the database this week and release 12-week topline โฆ
Tiziana Life Sciences has completed patient visits for its Phase 2a clinical trial of intranasal foralumab for non-active secondary progressive multiple sclerosis (na-SPMS). The company expects to announce topline data from the INFORM-MS trial in October, with an open-label extension to follow. This marks โฆ
Tiziana Life Sciences (TLSA) has signed a Memorandum of Understanding (MOU) with the King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, and the Foundation for Neurologic Diseases. This collaboration aims to conduct a clinical trial combining Tizianaโs intranasal โฆ
Tiziana Life Sciences stock surged over 21% on Thursday after the company announced a memorandum of understanding to evaluate a combination therapy for patients with relapsing-remitting multiple sclerosis. The biotechnology firm will collaborate with King Abdullah International Medical Research Center and the Foundation for โฆ
Tiziana Life Sciences (NASDAQ: TLSA) has signed a Memorandum of Understanding (MOU) with Saudi research institutions to initiate a clinical trial. This trial will investigate the use of intranasal foralumab in combination with anti-CD20 therapy for relapsing-remitting multiple sclerosis (RRMS) patients who have not โฆ
Tiziana Life Sciences has partnered with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to explore a combination therapy for multiple sclerosis. The collaboration will study intranasal foralumab alongside anti-CD20 therapy for relapsing-remitting MS patients who do not โฆ
Tiziana Life Sciences has signed an MOU with the King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases to collaborate on a clinical trial. This trial will investigate the efficacy of Tiziana's intranasal foralumab in combination with existing anti-CD20 therapy for โฆ
BTIG has issued a Buy rating for Tiziana Life Sciences (TLSA) with a $7 price target, citing the company's innovative Treg-based approach to neurodegeneration. The biotech is developing foralumab, a nasal spray, to reduce central nervous system inflammation, with potential for treating conditions like โฆ
BTIG has initiated coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and a price target of $7.00, citing the company's clinical-stage biotechnology focused on an anti-CD3 antibody, foralumab, for neurodegenerative diseases. The firm highlights the INFORM-MS trial in October 2026 as a โฆ
Tiziana Life Sciences announced a poster presentation at ALS Nexus 2026 detailing the Phase 2a BANYAN clinical trial of intranasal foralumab for Amyotrophic Lateral Sclerosis (ALS). The presentation by Dr. Pinar Uysal highlights the trial's design, preclinical data, and its focus on assessing safety, โฆ
This article highlights key market movers, including Expion Energy which saw a significant stock jump after closing an initial $9 million private placement for oil and gas exploration assets. Bitmine Immersion Technologies reported $14.9 billion in crypto holdings, while MicroStrategy raised $2.01 billion through โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States